当前位置: 首页 >> 检索结果
1841. [Ability of actin-regulatory protein, gelsolin in induction of monocytic leukemia cell differentiation].1842. [Development of a molecular target therapy on the basis of global gene analyses of gastrointestinal carcinoma].
作者: Yoshihiko Maehara.;Eiji Oki.;Eriko Tokunaga.;Shinichiro Maehara.;Eiji Tsujita.;Yoichi Yamashita.;Akinori Egashira.;Akinobu Taketomi.;Kakeji Yoshihiro.
来源: Fukuoka Igaku Zasshi. 2006年97卷2期30-6页 1843. [Molecular pathogenesis of multiple myeloma].1844. [Siblings with xeroderma pigmentosum group A showing mild cutaneous and various neurological manifestations].
作者: Satoshi Kuru.;Midori Yasuma.;Motoko Sakai.;Masaaki Konagaya.;Shinichi Moriwaki.
来源: Rinsho Shinkeigaku. 2006年46卷2期134-9页
We report siblings with xeroderma pigmentosum group A (XP-A) showing mild cutaneous and late-onset severe neurological manifestations. The elder brother first noticed unstability in walking at 16 years of age. Subsequently slowly progressive mental deterioration developed with cerebellar ataxia, spasticity, sensory disturbance, urinary dysfunction and vocal cord paralysis. His younger sister presented with dysarthria at 18 years of age. She showed manifestations similar to her brother's. Both of them suffered from sensitivity to the sun but no malignant skin tumor. They were diagnosed as XP-A by the measurement of unscheduled DNA synthesis and complementation analysis. Gene analyses revealed compound heterozygote for G-->C substitution at the 3' splicing acceptor site of intron 3 and insertion of 4 bases in exon 6 of XPA gene. It is suggested that transcription-coupled repair is dominantly affected with relative sparing of global genome repair in these siblings.
1845. [A case of retroperitoneal malignant peripheral nerve sheath tumor in a patient with neurofibromatosis].
作者: Tetsuya Miura.;Yuji Yamada.;Mototsugu Muramaki.;Kazushi Tanaka.;Isao Hara.;Masato Fujisawa.
来源: Hinyokika Kiyo. 2006年52卷3期207-9页
We report a case of retroperitoneal malignant peripheral nerve sheath tumor (MPNST) in a patient with neurofibromatosis 1. A 42-year-old woman was admitted because of a palpable left abdominal mass. Her mother, son, and daughter had neurofibromatosis 1. Computed tomography and magnetic resonance imaging revealed a 73 x 76 mm retroperitoneal mass. We performed complete resection of the tumor, confirming the margin status by frozen section examination intraoperatively. The histopathological examination revealed MPNST. Although no further therapy was performed, she is alive with no evidence of disease 11 months after surgery.
1846. [Epstein-Barr virus-associated gastric carcinoma].
作者: Shosuke Imai.;Masayuki Kuroda.;Yoshito Ishiura.;Norihiro Kotani.
来源: Nihon Rinsho. 2006年64 Suppl 3卷651-6页 1849. [Occult micrometastasis].
The concept of occult micrometastasis has been recognized for several decades. Recently, the balance of evidence favours the hypothesis that micrometastatic cells impacts on survival in spite of few clinical large-scale trials. Immunocytochemistry using anti-cytokeratin monoclonal antibodies is often used to detect micrometastatic cells. The strategy for detection of micrometastasis would help in the design of "tailor-made treatment". Furthermore, the genomic analyses of micrometastatic cells will contribute to the development of more effective strategies to treat cancer patients as well as the clarification of the carcinogenesis and the mechanism of clinical metastasis which is the leading cause of cancer-related death.
1850. [Genes involved in breast cancers].
作者: Toshikazu Ushijima.;Masanobu Abe.;Takao Maekita.;Eriko Okochi-Takada.
来源: Nihon Rinsho. 2006年64卷3期432-6页
Specific abnormalities in cancers are the best molecular targets of therapeutics, which is exemplified by trastuzumab. ERBB2 amplification is present in 15-30% of invasive ductal carcinomas, and its overexpression was associated with poor prognosis. c-MYC amplification is present in 13-19%, but other forms of oncogene activation are rare. Germline mutations of BRCA1 and BRCA2 are responsible for familial breast cancers. Their somatic mutations in sporadic breast cancers are rare, but chromosomal losses are frequent. Inactivation of BRCA1 by its promoter methylation is also frequent. p53 mutations are present in 20-25% of sporadic breast cancers, and inactivation of its pathway is present in most of them. Further molecular analysis will reveal new targets for diagnosis and therapeutics.
1851. [Tumor-specific gene therapy strategy for renal cell carcinomas].
作者: Masakazu Ogura.;Toru Shibata.;Hiroshi Harada.;Masahiro Hiraoka.
来源: Nihon Rinsho. 2006年64 Suppl 2卷672-5页 1852. [Therapeutic indication of interferons for renal cell carcinoma].1853. [Genetic backgrounds of renal cell carcinoma].1854. [Epigenetics and hematological disorders].1855. [Genetic diagnosis of biliary tract cancer].1856. [Genetic alterations in biliary tract carcinoma].1857. [Stem cell and cancer in bile epithelial cells].1858. [Genetic susceptibility to gallbladder cancer in Japanese].
作者: Yasuo Tsuchiya.;Kazutoshi Nakamura.;Masaharu Yamamoto.;Chikako Kiyohara.
来源: Nihon Rinsho. 2006年64 Suppl 1卷336-8页 1859. [Novel molecular-targeting peptide therapy for pancreatic cancer metastasis].
作者: Shinji Tanaka.;Noriaki Nakamura.;Tohru Kawamura.;Ken-ichi Teramoto.;Shigeki Arii.
来源: Nihon Rinsho. 2006年64 Suppl 1卷283-7页 1860. [Geneteic diagnosis for pancreatic tumors].
作者: Hiroyuki Watanabe.;Koushiro Ohtsubo.;Yasushi Yamaguchi.;Norio Sawabu.
来源: Nihon Rinsho. 2006年64 Suppl 1卷148-52页 |